Jupiter Neurosciences files Form D for $774,787 private offering
The Palm Beach Gardens company reported selling all of a $774,787 exempt securities offering to a single investor, per an SEC Form D filed September 4, 2026.
SEC filing
Latest
5 stories
Friday, September 4
Thursday, August 27
Jupiter Neurosciences executives forgive $875,315 in accrued pay
Four officers and directors waived unpaid compensation in agreements signed August 26, 2026, with no shares or cash exchanged in return.
SEC filing
Monday, August 24
Jupiter Neurosciences prices $2.0 million registered direct offering at $6.50 per share
The Nasdaq-listed CNS drug developer plans to close the sale of 307,692 shares on or about August 24, 2026, with proceeds earmarked for working capital.
SEC filing (2)
Tuesday, July 28
Jupiter Neurosciences sells $3.6M in stock to Yorkville under equity line
Between May 14 and July 24, 2026, Jupiter Neurosciences issued 11,470,000 shares to Yorkville under its standby equity purchase agreement, lifting total shares outstanding to 56,520,143.
SEC filing
Tuesday, July 21
Jupiter Neurosciences signs U.S. license deal with PharmAla for ALA-002
The definitive agreement replaces a May non-binding term sheet and sets upfront, milestone, and royalty payments tied to ALA-002 development in the U.S.
SEC filing